[Sublingual administration of apomorphine in the treatment of motor fluctuations in Parkinson disease]. 1992

F Durif, and D Deffond, and A Eschalier, and M Tournilhac
Service de Neurologie, Hôpital Fontmaure, Clermont-Ferrand.

Apomorphine, a mixed dopaminergic agonist was given sublingually to 12 patients with Parkinson's disease disabled by severe on-off fluctuations. The patient's mean age was 57 years and the duration of Parkinson's disease was 12 years. All patients were also given domperidone (60 mg/day). Apomorphine was administered as soon as the off periods appeared. On periods were observed in 11 patients, with a mean apomorphine dose of 40 mg for each administration (extremes values: 20-60 mg). One patient had no motor benefit after an apomorphine dose of 120 mg. The mean duration of daily off periods was reduced by 64 per cent in 11 patients, for a mean duration of 8 months (extremes values: 2-12 months). Four patients developed stomatitis or gingival edema and stopped treatment. This pilot study shows that sublingual apomorphine, during a mean period of 8 months, significantly decreases off periods in parkinsonian patients. Others studies are necessary to confirm these results.

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009043 Motor Activity Body movements of a human or an animal as a behavioral phenomenon. Activities, Motor,Activity, Motor,Motor Activities
D009069 Movement Disorders Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions. Dyskinesia Syndromes,Etat Marbre,Status Marmoratus,Movement Disorder Syndromes,Dyskinesia Syndrome,Movement Disorder,Movement Disorder Syndrome
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000286 Administration, Sublingual Administration of a soluble dosage form by placement under the tongue. Drug Administration, Sublingual,Sublingual Drug Administration,Sublingual Administration,Administration, Sublingual Drug,Administrations, Sublingual,Administrations, Sublingual Drug,Drug Administrations, Sublingual,Sublingual Administrations,Sublingual Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

F Durif, and D Deffond, and A Eschalier, and M Tournilhac
December 1991, Clinical neuropharmacology,
F Durif, and D Deffond, and A Eschalier, and M Tournilhac
April 2024, Journal of pharmacokinetics and pharmacodynamics,
F Durif, and D Deffond, and A Eschalier, and M Tournilhac
May 2024, Journal of pharmacokinetics and pharmacodynamics,
F Durif, and D Deffond, and A Eschalier, and M Tournilhac
January 1990, Revue neurologique,
F Durif, and D Deffond, and A Eschalier, and M Tournilhac
February 2020, JAMA,
F Durif, and D Deffond, and A Eschalier, and M Tournilhac
August 2018, Journal of neural transmission (Vienna, Austria : 1996),
F Durif, and D Deffond, and A Eschalier, and M Tournilhac
January 2006, Clinical neuropharmacology,
F Durif, and D Deffond, and A Eschalier, and M Tournilhac
September 2002, Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology,
F Durif, and D Deffond, and A Eschalier, and M Tournilhac
September 1991, Ugeskrift for laeger,
F Durif, and D Deffond, and A Eschalier, and M Tournilhac
June 1987, Lancet (London, England),
Copied contents to your clipboard!